- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Dr. Yu Baofa nechikwata chekuUnited States vakaburitsa chinyorwa muJournal of Gastroenterology Research and Practice.
2025-02-11
Chiremba Yu Baofa nechikwata cheAmerica vakabatana vakaburitsa chinyorwa cheOngororo yeakawanda autoantibodies kune bundu rine chekuita nemaantigens sezvingangoita diagnostic marker epancreatic cancer muJournal yeGastroenterology Research and Practice.
Chinangwa chechidzidzo ichi chaive chekuongorora kukosha kwekiriniki yeautoantibodies kurwisa GNA11, MSLN, GNAS, CEBPA, MDM2, p16, Sui1, Calnuc, PTEN mupancreatic cancer (PC). Zvose zve 33 serum samples kubva kuvarwere vePC uye 45 serum samples kubva kune zvakajairika kutonga (NC) zvakabatanidzwa, uye 9 marudzi e autoantibodies akaonekwa achishandisa enzyme-linked immunosorbent assay (ELISA). Ongorora uchishandisa akawanda ma parameter mune imwe neimwe kana yakasanganiswa fomu. Kunze kweanti GNAS uye anti calNUC, mazinga emamwe ese autoantibodies aive akakwira zvakanyanya kupfuura ayo ari muboka rekutonga. Kuenzaniswa neyakajairwa kudzora boka (4.9%), iyo frequencies yechina autoantibodies, MSLN, p16, PTEN, uye Sui1, yakawedzera zvakanyanya, pa75.8%, 66.7%, 30.3%, uye 27.3%, zvichiteerana. Kugona kweaya autoantibodies kusiyanisa nzvimbo iri pasi peROC curve (AUC) inotangira pa0.666 kusvika 0.884, ine anti-p16 (AUC ye0.884) uye anti MSLN (AUC ye0.857) ichiratidza kushanda kwakasimba kwekuongorora. Iko kusanganiswa kweAnti-MSLN uye anti-p16 kunogona kuvandudza kunzwa kwekuongororwa.
Uye zvakare, ese MSLN uye Sui1 autoantibodies yakadzikira muPC varwere mushure mechemotherapy. Zvina autoantibodies zvichipesana neMSLN, p16, Sui1 uye PTEN zvakaratidza zvingangoitika zvekuongorora kenza yepancreatic, iyo anti MSLN uye anti p16 yaive yakanyanya kunaka. Iko kusanganiswa kweaya maviri autoantibodies anoratidza yakanyanya hupfumi uye inoshanda kugona. Kukosha kwekudzikira autoantibodies kurwisa MSLN uye Sui1 muPC varwere mushure mechemotherapy inoda kumwe kuongororwa.
Tsvagiridzo ye tumor inoenderana ne autoantibodies inopa yakakosha kutariswa kwekutanga kuongororwa, kuongororwa, uye kurapwa kwemamota. Academician Yu Baofa akaisa tumor autoantibodies mukurapa bundu makore anopfuura makumi maviri apfuura.
